BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia

Journal of Clinical Investigation

Volumn 124, Issue 11, 2014, Pages 5074-5084

  Yaktapour, Niuscha ^a,b   Meiss, Frank ^a   Mastroianni, Justin ^a,b   Zenz, Thorsten ^c,d   Andrlova, Hana ^a   Mathew, Nimitha R ^a,b   Claus, Rainer ^a   Hutter, Barbara ^c   Fröhling, Stefan ^c   Brors, Benedikt ^c   Pfeifer, Dietmar ^a   Pantic, Milena ^a   Bartsch, Ingrid ^a   Spehl, Timo S ^a   Meyer, Philipp T ^a   Duyster, Justus ^a,e   Zirlik, Katja ^a   Brummer, Tilman ^b,f   Zeiser, Robert ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e DKTK   (Germany)

^f Institute for Molecular Medicine and Cell Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; B LYMPHOCYTE RECEPTOR; B RAF KINASE; BRUTON TYROSINE KINASE; DABRAFENIB; GUANOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE SYK; RAS PROTEIN; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MELANOMA; MOUSE; NONHUMAN; RECEPTOR UPREGULATION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; PHOSPHORYLATION; PROTEIN PROCESSING; SCINTISCANNING; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MAP KINASE SIGNALING SYSTEM; MELANOMA; MIDDLE AGED; MUTATION, MISSENSE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84908615009     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI76539     Document Type: Article

References (48)

1. Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
2. Heidorn SJ, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209-221.
3. Röring M, et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J. 2012;31(11):2629-2647.
4. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427-430.
5. Hatzivassiliou G, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431-435.
6. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23(2):177-182.
7. Zimmer L, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30(19):2375-2383.
8. Su F, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207-215.
9. Nazarian R, Shi H, Wang Q, Kong X. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-977.
10. Callahan MK, et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med. 2012;367(24):2316-2321.
11. Carlino MS, et al. New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma [published online ahead of print May 12, 2014]. J Clin Oncol. doi:10.1200/JCO.2013.51.5783.
12. Röring M, Brummer T. Aberrant B-Raf signaling in human cancer - 10 years from bench to bedside. Crit Rev Oncog. 2012;17(1):97-121.
13. Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013;19(11):1401-1409.
14. Balch CM, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
15. Ouillette P, et al. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clin Cancer Res. 2011;17(21):6778-6790.
16. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854.
17. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12(3):229-243.
18. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101(3):1087-1093.
19. Flaherty KT, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
20. Menzies AM, Long GV. Dabrafenib and trametinib, alone and in combination for BRAF mutant metastatic melanoma. Clin Cancer Res. 2014;20(8):2035-2043.
21. Jethwa A, et al. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. Br J Haematol. 2013;163(4):496-500.
22. Brummer T, Shaw PE, Reth M, Misawa Y. Inducible gene deletion reveals different roles for B-Raf and Raf-1 in B-cell antigen receptor signalling. EMBO J. 2002;21(21):5611-5622.
23. Yasuda T, et al. Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion. Immunity. 2008;28(4):499-508.
24. Buchner M, et al. Spleen tyrosine kinase inhibition prevents chemokine- And integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood. 2010;115(22):4497-4506.
25. Quiroga MP, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009;114(5):1029-1037.
26. Buchner M, Müschen M. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol. 2014;21(4):341-349.
27. Reth M, Brummer T. Feedback regulation of lymphocyte signalling. Nat Immunol. 2004;4(3):269-277.
28. Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-1703.
29. Dühren-von Minden M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489(7415):309-312.
30. Friedberg JW, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lympho-cytic leukemia. Blood. 2010;115(13):2578-2585.
31. Andrews MC, et al. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clin Oncol. 2013;31(35):e448-e451.
32. Vin H, et al. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. eLife. 2013;2:e00969.
33. Flaherty KT, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
34. Ascierto PA, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013;31(26):3205-3211.
35. Falchook GS, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893-1901.
36. Hauschild A, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
37. Long GV, et al. Dabrafenib in patients with Val- 600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087-1095.
38. Lorenzo Bermejo J, Pukkala E, Johannesen TB, Sundquist J, Hemminki K. Age-time risk patterns of solid cancers in 60 901 non-Hodgkin lymphoma survivors from Finland, Norway and Sweden. Br J Haematol. 2014;164(5):675-683.
39. Brewer JD, Habermann TM, Shanafelt TD. Lymphoma- Associated skin cancer: incidence, natural history, and clinical management. Int J Dermatol. 2014;53(3):267-274.
40. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1):55-63.
41. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-1760.
42. Li H, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-2079.
43. Jones DT, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012;488(7409):100-105.
44. Jones DTW, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45(8):927-932.
45. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from highthroughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.
46. Robinson JT, et al. Integrative genomics viewer. Nat Biotech. 2011;29(1):24-26.
47. Koboldt DC, et al. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;2(3):568-576.
48. Quinlan AR, Hall IM. BEDTools: A flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;15(6):841-842.